Tag: disease-modifying therapy (DMT)


Reproductive Issues and Multiple Sclerosis: 20 Frequently Asked Questions

The disease is not a barrier to pregnancy, but risks from disease-modifying therapies must be managed

23-NEU-3991918 CQD hero_650x450

For Older Patients With Multiple Sclerosis, Discontinuing Disease-Modifying Therapy May Be an Option

Risk of new MS activity is small in those older than 55 with stable disease who stop MS therapy


DELIVER-MS Trial Extended to Guide Philosophy for Long-Term Multiple Sclerosis Therapy

$1.1M award expands follow-up to six years with focus on clinical endpoints

April 28, 2023/Neurosciences/Pediatrics

Switching Disease-Modifying Therapies in Pediatric Multiple Sclerosis: Insights From Real-World Data

Relapse rates were lower with oral or infusion therapy after initial injectable DMT


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

March 16, 2023/Neurosciences/Podcast

Leveraging Real-World Evidence for Treating Multiple Sclerosis (Podcast)

Observational studies comparing disease-modifying therapies can help guide clinical decisions

November 12, 2021/COVID-19

Breakthrough COVID-19 in Patients With Multiple Sclerosis: Snapshot From One Data Registry

Unlikely to be severe, infections are associated with anti-CD20 therapies and fingolimod

COVID-19 hero-650×450
April 27, 2020/COVID-19

Managing Multiple Sclerosis During the COVID-19 Pandemic

What to do with what we know, and how we’re gathering more data

November 12, 2018/Neurosciences/Research

Disease-Modifying Therapy for MS: Discontinuing After Age 60 Appears Safe

Observational study suggests age may be a better guide than disease stability


AAN Releases New Practice Guideline on Disease-Modifying Therapies for Multiple Sclerosis

Lead author Alexander Rae-Grant, MD, shares what’s new and notable

BackPage 1 of 1Next